Anti-clotting treatment apixaban outperforms Lovenox in study

03/4/2010 | Reuters

Apixaban beat standard treatment Lovenox in preventing blood clots without increasing the risk of bleeding during a late-stage trial in patients who underwent knee surgery. Apixaban is a product of Pfizer and Bristol-Myers Squibb, which plan to submit the drug for European approval this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY